Johnson & Johnson says AI halves time to optimize drug leads, speeds regulatory document prep
Johnson & Johnson is applying artificial intelligence to reduce lead optimization time in drug development by roughly 50%, and has dramatically shortened the time to prepare clinical trial documentation for regulators, the company’s chief information officer said. While AI is not yet able to discover and bring new products to market on its own, J&J…